IP Library › Granted Patent US 9,062,306
Granted Patent B2
US 9,062,306 · App. 10/834,525 · Granted Jun 23, 2015

Methods for identifying compounds for treating type 1 diabetes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,062,306
App. No.
10/834,525
Granted
Jun 23, 2015
Kind
B2
Abstract

The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes by identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells.

Claims (8)

1. A method of identifying candidate compounds for the treatment of type 1 diabetes comprising

(a) contacting pancreatic β cells with

(i) one or more test compounds and

(ii) an amount of human apolipoprotein CIII (“apoCIII”) according to SEQ ID NO: 2 that would be effective to increase intracellular calcium concentration in the pancreatic β cells in the absence of the one or more test compounds, and

(b) identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells,

wherein such test compounds are candidate compounds for the treatment of type 1 diabetes.

2. The method of claim 1 wherein the apoCIII comprises sialylated apoCIII.

3. The method of claim 1 wherein the apoCIII is substantially purified.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2007
From: BIOSTRATUM AB
To: BIOCRINE AB
Reel/Frame 019698/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2007
From: BIOSTRATUM, INC.
To: BIOSTRATUM AB
Reel/Frame 019360/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2004
From: BERGGREN, PER-OLOF
To: BIOSTRATUM, INC.
Reel/Frame 015095/0966 →